Invasive pulmonary aspergillosis and candidiasis in a critically ill patient with COVID-19.
作者信息
Benedetti María Fernanda, de Abreu Mariela Soledad, Cadena Roberto Corella, Arias María Constanza, Posse Gladys, Capece Paula, Nusblat Alejandro, Cuestas María Luján
机构信息
Servicio de Infectología, Hospital NacionalProfesor Alejandro Posadas,Buenos Aires, Argentina.
Universidad de Buenos Aires, Instituto de Investigaciones en Microbiología y Parasitología Médica (IMPaM, UBA-CONICET), Buenos Aires, Argentina.
出版信息
J Mycol Med. 2022 May;32(2):101251. doi: 10.1016/j.mycmed.2022.101251. Epub 2022 Jan 31.
Abstract
摘要
相似文献
1
Invasive pulmonary aspergillosis and candidiasis in a critically ill patient with COVID-19.
J Mycol Med. 2022 May;32(2):101251. doi: 10.1016/j.mycmed.2022.101251. Epub 2022 Jan 31.
2
Invasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices.
APMIS. 2023 Nov;131(11):654-667. doi: 10.1111/apm.13316. Epub 2023 Apr 25.
3
A screening study for COVID-19-associated pulmonary aspergillosis in critically ill patients during the third wave of the pandemic.
Mycoses. 2022 Jul;65(7):724-732. doi: 10.1111/myc.13466. Epub 2022 May 25.
4
[Invasive fungal infections in ICU patients - What's New?].
Dtsch Med Wochenschr. 2021 Apr;146(7):455-460. doi: 10.1055/a-1267-0763. Epub 2021 Mar 29.
5
Prognostic Impact of Bronchoalveolar Lavage Fluid Galactomannan and Aspergillus Culture Results on Survival in COVID-19 Intensive Care Unit Patients: a Analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-Associated Pulmonary Aspergillosis Study.
J Clin Microbiol. 2022 Apr 20;60(4):e0229821. doi: 10.1128/jcm.02298-21. Epub 2022 Mar 24.
6
COVID-19-associated pulmonary aspergillosis (CAPA): Risk factors and development of a predictive score for critically ill COVID-19 patients.
Mycoses. 2022 May;65(5):541-550. doi: 10.1111/myc.13434. Epub 2022 Mar 15.
7
Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Nationwide, Multicenter, Retrospective Cohort Study.
J Korean Med Sci. 2022 May 9;37(18):e134. doi: 10.3346/jkms.2022.37.e134.
8
Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, non-neutropenic, adult patients: An update including COVID-19 data.
J Infect. 2022 Nov;85(5):573-607. doi: 10.1016/j.jinf.2022.08.003. Epub 2022 Aug 5.
9
[COVID-19-associated pulmonary aspergillosis in critically ill patients: experience of a Chilean public hospital].
Rev Chilena Infectol. 2021 Dec;38(6):754-760. doi: 10.4067/s0716-10182021000600754.
10
Invasive pulmonary aspergillosis in critically ill patients with COVID-19 in Australia: implications for screening and treatment.
Intern Med J. 2021 Dec;51(12):2129-2132. doi: 10.1111/imj.15602.
引用本文的文献
1
Global burden of reported lower respiratory system fungal infection.
Front Cell Infect Microbiol. 2025 Feb 14;15:1542922. doi: 10.3389/fcimb.2025.1542922. eCollection 2025.
2
A self-immolative Kdn-glycoside substrate enables high-throughput screening for inhibitors of Kdnases.
Glycobiology. 2025 Jan 13;35(1). doi: 10.1093/glycob/cwae094.
3
Typing of spp. from Colonized COVID-19 Patients Reveal Virulent Genetic Backgrounds and Clonal Dispersion.
Pathogens. 2023 Sep 29;12(10):1206. doi: 10.3390/pathogens12101206.
4
The Argentinian landscape of mycological diagnostic capacity and treatment accessibility.
Med Mycol. 2023 Jun 5;61(6). doi: 10.1093/mmy/myad058.
本文引用的文献
1
Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study.
Lancet Respir Med. 2022 Feb;10(2):180-190. doi: 10.1016/S2213-2600(21)00442-2. Epub 2021 Nov 26.
2
COVID-19-Associated Pulmonary Aspergillosis, Fungemia, and Pneumocystosis in the Intensive Care Unit: a Retrospective Multicenter Observational Cohort during the First French Pandemic Wave.
Microbiol Spectr. 2021 Oct 31;9(2):e0113821. doi: 10.1128/Spectrum.01138-21. Epub 2021 Oct 20.
3
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.
Lancet Infect Dis. 2021 Jun;21(6):e149-e162. doi: 10.1016/S1473-3099(20)30847-1. Epub 2020 Dec 14.
4
Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity.
Mycoses. 2021 Feb;64(2):132-143. doi: 10.1111/myc.13213. Epub 2020 Nov 29.
5
COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions?
J Fungi (Basel). 2020 Oct 8;6(4):211. doi: 10.3390/jof6040211.
6
Fungal co-infection in COVID-19 patients: Should we be concerned?
Rev Iberoam Micol. 2020 Apr-Jun;37(2):41-46. doi: 10.1016/j.riam.2020.07.001. Epub 2020 Sep 14.
7
SARS-CoV-2-induced immunodysregulation and the need for higher clinical suspicion for co-infection and secondary infection in COVID-19 patients.
J Microbiol Immunol Infect. 2021 Feb;54(1):105-108. doi: 10.1016/j.jmii.2020.08.016. Epub 2020 Sep 8.
8
Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China.
Mycopathologia. 2020 Aug;185(4):599-606. doi: 10.1007/s11046-020-00462-9. Epub 2020 Jul 31.
9
Critically ill patients with COVID-19 and candidaemia: We must keep this in mind.
J Mycol Med. 2020 Dec;30(4):101012. doi: 10.1016/j.mycmed.2020.101012. Epub 2020 Jul 4.
10
Bloodstream infections in critically ill patients with COVID-19.
Eur J Clin Invest. 2020 Oct;50(10):e13319. doi: 10.1111/eci.13319. Epub 2020 Aug 11.
Zotero 插件